Most Users Report Cannabidiol Use for Treatment of Diagnosable Conditions
Psychiatric, orthopedic, and sleep issues most commonly cited in a Reddit forum
Gastrohepatic Disorders
Management of Remdesivir-Associated Acute Liver Failure Examined in Case Series
Remdesivir was immediately discontinued in both patients and a continuous infusion of acetylcysteine was initiated.
ACS: Antibiotics Noninferior to Appendectomy for Appendicitis
However, complications occurred more often in the antibiotics group than in the appendectomy group.
Proton Pump Inhibitor Use Linked to Increased Diabetes Risk
Type 2 diabetes risk increased with increasing length of PPI use, particularly use for more than two years.
FDA Rejects Terlipressin NDA for Hepatorenal Syndrome Type 1
In July 2020, the FDA Cardiovascular and Renal Drugs Advisory Committee narrowly voted 8 to 7 in favor of the approval of terlipressin for HRS-1.
FDA Fast Tracks SSAO Inhibitor for Nonalcoholic Steatohepatitis
TERN-201 is a highly-selective semicarbazide-sensitive amino oxidase inhibitor.
Reduced CDI Recurrence Observed With Investigational Microbiome Therapy
SER-109 contains purified bacterial spores of multiple Firmicute species obtained from the stool of healthy human donors.
Ortikos Now Available for Mild to Moderate Crohn Disease
Ortikos, an anti-inflammatory corticosteroid, is approved as a once-daily treatment for mild to moderate active Crohn disease and for maintenance of clinical remission.
Clinical Hold Lifted on Seladelpar for Chronic Liver Diseases
The FDA has lifted the clinical hold on 3 Investigational New Drug applications evaluating seladelpar (CymaBay Therapeutics) for the treatment of non-alcoholic steatohepatitis, primary biliary cholangitis and primary sclerosing cholangitis.
Efficacy of Cannabinoids in Treating IBD Examined
Significant improvements in both clinical symptoms (ie, abdominal pain, general well-being, nausea, diarrhea, and decreased appetite) as well as QoL scores were observed with cannabinoids.
